Notably, there is a lack of studies in the Middle East reporting on the outcomes of glucagon-like peptide 1 (GLP-1) receptor agonists in treating obesity in children and adolescents, with or without diabetes. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.